- European Commission approves Sandoz Erelzi® to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis
- Approval of Erelzi provides more treatment options for healthcare professionals and patients and opens another chapter in the Sandoz immunology portfolio
- Sandoz now has five biosimilars approved in Europe, including biosimilars of some of the world’s leading blockbuster biologics1
Holzkirchen, June 27, 2017 — Sandoz, a Novartis …